1. Home
  2. FLC vs URGN Comparison

FLC vs URGN Comparison

Compare FLC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLC
  • URGN
  • Stock Information
  • Founded
  • FLC 2003
  • URGN 2004
  • Country
  • FLC United States
  • URGN United States
  • Employees
  • FLC N/A
  • URGN N/A
  • Industry
  • FLC Trusts Except Educational Religious and Charitable
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • FLC Finance
  • URGN Health Care
  • Exchange
  • FLC Nasdaq
  • URGN Nasdaq
  • Market Cap
  • FLC 174.2M
  • URGN 181.2M
  • IPO Year
  • FLC N/A
  • URGN 2017
  • Fundamental
  • Price
  • FLC $16.31
  • URGN $13.58
  • Analyst Decision
  • FLC
  • URGN Strong Buy
  • Analyst Count
  • FLC 0
  • URGN 8
  • Target Price
  • FLC N/A
  • URGN $23.00
  • AVG Volume (30 Days)
  • FLC 37.8K
  • URGN 5.5M
  • Earning Date
  • FLC 01-01-0001
  • URGN 08-12-2025
  • Dividend Yield
  • FLC 6.64%
  • URGN N/A
  • EPS Growth
  • FLC N/A
  • URGN N/A
  • EPS
  • FLC N/A
  • URGN N/A
  • Revenue
  • FLC N/A
  • URGN $91,871,000.00
  • Revenue This Year
  • FLC N/A
  • URGN $36.65
  • Revenue Next Year
  • FLC N/A
  • URGN $88.35
  • P/E Ratio
  • FLC N/A
  • URGN N/A
  • Revenue Growth
  • FLC N/A
  • URGN 8.98
  • 52 Week Low
  • FLC $12.62
  • URGN $3.42
  • 52 Week High
  • FLC $15.45
  • URGN $18.15
  • Technical
  • Relative Strength Index (RSI)
  • FLC 65.10
  • URGN 63.17
  • Support Level
  • FLC $16.86
  • URGN $12.73
  • Resistance Level
  • FLC $17.09
  • URGN $13.93
  • Average True Range (ATR)
  • FLC 0.12
  • URGN 1.24
  • MACD
  • FLC 0.01
  • URGN -0.00
  • Stochastic Oscillator
  • FLC 84.21
  • URGN 50.49

About FLC Flaherty & Crumrine Total Return Fund Inc

Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: